<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_mitotane" title="Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment" shortTitle="mitotane" author="Soraya Puglisi, Anna Calabrese, Vittoria Basile, Filippo Ceccato, Carla Scaroni, Chiara Simeoli, Massimo Torlontano, Salvatore Cannavò, Giorgio Arnaldi, Antonio Stigliano, Pasqualino Malandrino, Laura Saba, Barbara Altieri, Silvia Della Casa, Paola Perotti, Paola Berchialla, Giuseppina De Filpo, Letizia Canu, Paola Loli, Giuseppe Reimondo, Massimo Terzolo" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2077-0383/8/11/1850/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
4.	LS	4.
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
The	DT	the
present	JJ	present
study	NN	study
confirms	VBZ	confirm
that	IN	that
a	DT	a
remarkable	JJ	remarkable
number	NN	number
of	IN	of
patients	NNS	patient
with	IN	with
ACC	NNP	ACC
who	WP	who
are	VBP	be
operated	VBN	operate
on	IN	on
with	IN	with
radical	JJ	radical
intent	NN	intent
are	VBP	be
destined	VBN	destine
to	TO	to
relapse	VB	relapse
.	.	.
</s>
<s type="frag">
ACC	NNP	ACC
</s>
<s type="decl">
recurrence	NN	recurrence
portends	VBZ	portend
a	DT	a
worse	JJR	bad
prognosis	NN	prognosis
and	CC	and
has	VBZ	have
a	DT	a
huge	JJ	huge
impact	NN	impact
on	IN	on
quality	NN	quality
of	IN	of
life	NN	life
;	:	;
</s>
<s type="decl">
therefore	RB	therefore
,	,	,
investigators	NNS	investigator
have	VBP	have
considered	VBN	consider
the	DT	the
use	NN	use
of	IN	of
adjuvant	JJ	adjuvant
mitotane	NN	mitotane
therapy	NN	therapy
following	VBG	follow
surgical	JJ	surgical
operation	NN	operation
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
a	DT	a
limited	JJ	limited
number	NN	number
of	IN	of
often	RB	often
small-sized	JJ	small-sized
studies	NNS	study
reporting	VBG	report
the	DT	the
outcome	NN	outcome
of	IN	of
adjuvant	NN	adjuvant
mitotane	NN	mitotane
is	VBZ	be
available	JJ	available
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PRP	we
explored	VBD	explore
the	DT	the
relationship	NN	relationship
between	IN	between
target	NN	target
mitotane	NN	mitotane
concentrations	NNS	concentration
and	CC	and
patient	JJ	patient
outcome	NN	outcome
using	VBG	use
the	DT	the
TTR	NN	TTR
,	,	,
analogous	JJ	analogous
to	IN	to
warfarin	NN	warfarin
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
Some	DT	some
previous	JJ	previous
studies	NNS	study
used	VBD	use
the	DT	the
peak	NN	peak
mitotane	NN	mitotane
level	NN	level
,	,	,
which	WDT	which
cannot	MD	cannot
give	VB	give
an	DT	a
adequate	JJ	adequate
representation	NN	representation
since	IN	since
it	PRP	it
is	VBZ	be
a	DT	a
measurement	NN	measurement
at	IN	at
a	DT	a
single	JJ	single
point	NN	point
in	IN	in
time	NN	time
.	.	.
</s>
<s type="decl">
In	IN	in
other	JJ	other
studies	NNS	study
,	,	,
the	DT	the
percentage	NN	percentage
of	IN	of
mitotane	NN	mitotane
measurements	NNS	measurement
in	IN	in
a	DT	a
range	NN	range
was	VBD	be
used	VBN	use
,	,	,
but	CC	but
this	DT	this
method	NN	method
has	VBZ	have
the	DT	the
caveat	NN	caveat
of	IN	of
being	VBG	be
strongly	RB	strongly
dependent	JJ	dependent
on	IN	on
the	DT	the
number	NN	number
of	IN	of
available	JJ	available
measurements	NNS	measurement
.	.	.
</s>
<s type="decl">
This	DT	this
may	MD	may
introduce	VB	introduce
a	DT	a
bias	NN	bias
when	WRB	when
comparing	VBG	compare
patients	NNS	patient
with	IN	with
different	JJ	different
durations	NNS	duration
of	IN	of
follow-ups	NNS	follow-up
,	,	,
which	WDT	which
may	MD	may
be	VB	be
quite	RB	quite
prolonged	JJ	prolonged
in	IN	in
the	DT	the
case	NN	case
of	IN	of
adjuvant	NN	adjuvant
therapy	NN	therapy
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
there	EX	there
is	VBZ	be
no	DT	no
evidence	NN	evidence
to	TO	to
define	VB	define
what	WDT	what
percentage	NN	percentage
level	NN	level
identifies	VBZ	identify
a	DT	a
good	JJ	good
exposure	NN	exposure
to	IN	to
mitotane	NN	mitotane
.	.	.
</s>
<s type="sub">
These	DT	this
methodological	JJ	methodological
issues	NNS	issue
may	MD	may
have	VB	have
contributed	VBN	contribute
to	IN	to
the	DT	the
discrepancy	NN	discrepancy
in	IN	in
the	DT	the
literature	NN	literature
concerning	VBG	concern
adjuvant	JJ	adjuvant
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PRP	we
calculated	VBD	calculate
the	DT	the
TTR	NNP	TTR
,	,	,
which	WDT	which
in	IN	in
our	PRP$	our
opinion	NN	opinion
gives	VBZ	give
a	DT	a
more	RBR	more
adequate	JJ	adequate
representation	NN	representation
of	IN	of
chronic	JJ	chronic
exposure	NN	exposure
to	IN	to
mitotane	NN	mitotane
,	,	,
and	CC	and
analyzed	VBD	analyze
the	DT	the
results	NNS	result
in	IN	in
a	DT	a
multivariate	JJ	multivariate
analysis	NN	analysis
without	IN	without
predefining	VBG	predefine
arbitrary	JJ	arbitrary
cutoff	NN	cutoff
values	NNS	value
.	.	.
</s>
<s type="decl">
We	PRP	we
found	VBD	find
an	DT	a
inverse	JJ	inverse
relationship	NN	relationship
between	IN	between
the	DT	the
TTR	NN	TTR
and	CC	and
risk	NN	risk
of	IN	of
ACC	NN	ACC
recurrence	NN	recurrence
,	,	,
implying	VBG	imply
that	IN	that
the	DT	the
greater	JJR	great
the	DT	the
TTR	NNP	TTR
,	,	,
the	DT	the
lower	JJR	low
the	DT	the
risk	NN	risk
.	.	.
</s>
<s type="decl">
This	DT	this
finding	NN	finding
supports	VBZ	support
the	DT	the
clinical	JJ	clinical
value	NN	value
of	IN	of
mitotane	NN	mitotane
monitoring	NN	monitoring
and	CC	and
the	DT	the
concept	NN	concept
of	IN	of
target	NN	target
doses	NNS	dose
in	IN	in
the	DT	the
adjuvant	NN	adjuvant
setting	NN	setting
.	.	.
</s>
<s type="decl">
Although	IN	although
it	PRP	it
is	VBZ	be
plausible	JJ	plausible
that	IN	that
lower	JJR	low
mitotane	NN	mitotane
concentrations	NNS	concentration
may	MD	may
be	VB	be
effective	JJ	effective
in	IN	in
an	DT	a
adjuvant	JJ	adjuvant
treatment	NN	treatment
,	,	,
we	PRP	we
analyzed	VBD	analyze
only	RB	only
the	DT	the
level	NN	level
of	IN	of
14	CD	14
mg/L	NNS	mg/L
,	,	,
because	IN	because
this	DT	this
was	VBD	be
the	DT	the
target	NN	target
in	IN	in
our	PRP$	our
practice	NN	practice
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
time	NN	time
needed	VBN	need
to	TO	to
achieve	VB	achieve
target	NN	target
mitotane	NN	mitotane
concentrations	NNS	concentration
also	RB	also
has	VBZ	have
an	DT	a
impact	NN	impact
on	IN	on
the	DT	the
risk	NN	risk
of	IN	of
ACC	NN	ACC
recurrence	NN	recurrence
:	:	:
a	DT	a
longer	JJR	long
time	NN	time
was	VBD	be
associated	VBN	associate
with	IN	with
higher	JJR	high
risk	NN	risk
.	.	.
</s>
<s type="decl">
This	DT	this
is	VBZ	be
consistent	JJ	consistent
with	IN	with
the	DT	the
concept	NN	concept
that	IN	that
mitotane	NN	mitotane
is	VBZ	be
a	DT	a
slow-acting	JJ	slow-acting
drug	NN	drug
in	IN	in
relation	NN	relation
to	IN	to
the	DT	the
achievement	NN	achievement
of	IN	of
significant	JJ	significant
plasma	NN	plasma
levels	NNS	level
.	.	.
</s>
<s type="decl">
Due	JJ	due
to	IN	to
the	DT	the
very	RB	very
cautious	JJ	cautious
dose	NN	dose
titration	NN	titration
in	IN	in
the	DT	the
starting	VBG	start
phase	NN	phase
of	IN	of
treatment	NN	treatment
employed	VBN	employ
in	IN	in
many	JJ	many
centers	NNS	center
,	,	,
the	DT	the
time	NN	time
needed	VBN	need
to	TO	to
get	VB	get
into	IN	into
the	DT	the
target	NN	target
range	NN	range
was	VBD	be
exceedingly	RB	exceedingly
long	JJ	long
.	.	.
</s>
<s type="decl">
We	PRP	we
identified	VBD	identify
a	DT	a
time	NN	time
point	NN	point
at	IN	at
17	CD	17
months	NNS	month
to	TO	to
achieve	VB	achieve
target	NN	target
concentrations	NNS	concentration
,	,	,
which	WDT	which
significantly	RB	significantly
differentiates	VBZ	differentiate
patients	NNS	patient
for	IN	for
their	PRP$	their
risk	NN	risk
of	IN	of
recurrence	NN	recurrence
.	.	.
</s>
<s type="decl">
The	DT	the
present	JJ	present
findings	NNS	finding
call	VBP	call
for	IN	for
a	DT	a
change	NN	change
in	IN	in
practice	NN	practice
,	,	,
aiming	VBG	aim
for	IN	for
a	DT	a
faster	JJR	fast
rise	NN	rise
in	IN	in
mitotane	NN	mitotane
levels	NNS	level
and	CC	and
strengthening	VBG	strengthen
the	DT	the
value	NN	value
of	IN	of
mitotane	NN	mitotane
monitoring	NN	monitoring
.	.	.
</s>
<s type="sub">
However	RB	however
,	,	,
the	DT	the
potential	JJ	potential
danger	NN	danger
of	IN	of
a	DT	a
rapid	JJ	rapid
increment	NN	increment
in	IN	in
mitotane	NN	mitotane
dosing	NN	dosing
,	,	,
which	WDT	which
may	MD	may
result	VB	result
in	IN	in
important	JJ	important
toxicity	NN	toxicity
with	IN	with
consequent	JJ	consequent
loss	NN	loss
of	IN	of
compliance	NN	compliance
to	IN	to
treatment	NN	treatment
,	,	,
should	MD	should
be	VB	be
considered	VBN	consider
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
found	VBD	find
only	RB	only
a	DT	a
weak	JJ	weak
relationship	NN	relationship
between	IN	between
mitotane	NN	mitotane
dose	NN	dose
and	CC	and
its	PRP$	its
plasma	NN	plasma
concentrations	NNS	concentration
during	IN	during
the	DT	the
first	JJ	first
phase	NN	phase
of	IN	of
treatment	NN	treatment
,	,	,
and	CC	and
this	DT	this
finding	NN	finding
is	VBZ	be
in	IN	in
agreement	NN	agreement
with	IN	with
the	DT	the
concept	NN	concept
that	IN	that
individual	JJ	individual
differences	NNS	difference
in	IN	in
mitotane	NN	mitotane
metabolism	NN	metabolism
and	CC	and
other	JJ	other
still	RB	still
unknown	JJ	unknown
factors	NNS	factor
influence	VBP	influence
plasma	NN	plasma
concentrations	NNS	concentration
.	.	.
</s>
<s type="decl">
Interestingly	RB	interestingly
,	,	,
higher	JJR	high
doses	NNS	dose
were	VBD	be
employed	VBN	employ
in	IN	in
men	NNS	man
and	CC	and
in	IN	in
patients	NNS	patient
with	IN	with
greater	JJR	great
BMI	NN	BMI
and	CC	and
these	DT	this
novel	JJ	novel
findings	NNS	finding
matter	VBP	matter
for	IN	for
clinical	JJ	clinical
practice	NN	practice
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
our	PRP$	our
cohort	NN	cohort
,	,	,
toxicity	NN	toxicity
associated	VBN	associate
with	IN	with
adjuvant	NN	adjuvant
mitotane	NN	mitotane
was	VBD	be
acceptable	JJ	acceptable
,	,	,
though	IN	though
we	PRP	we
acknowledge	VBP	acknowledge
the	DT	the
fact	NN	fact
that	IN	that
due	JJ	due
to	IN	to
the	DT	the
study	NN	study
inclusion	NN	inclusion
criteria	NNS	criterion
we	PRP	we
did	VBD	do
not	RB	not
capture	VB	capture
the	DT	the
patients	NNS	patient
who	WP	who
eventually	RB	eventually
discontinued	VBD	discontinue
mitotane	NN	mitotane
in	IN	in
the	DT	the
first	JJ	first
six	CD	6
months	NNS	month
.	.	.
</s>
<s type="decl">
Severe	JJ	Severe
toxicity	NN	toxicity
leading	VBG	lead
to	IN	to
permanent	JJ	permanent
treatment	NN	treatment
discontinuation	NN	discontinuation
was	VBD	be
recorded	VBN	record
in	IN	in
only	RB	only
five	CD	5
patients	NNS	patient
on	IN	on
chronic	JJ	chronic
therapy	NN	therapy
,	,	,
and	CC	and
this	DT	this
is	VBZ	be
likely	JJ	likely
due	JJ	due
to	IN	to
the	DT	the
low	JJ	low
doses	NNS	dose
(	-LRB-	(
median	JJ	median
dose	NN	dose
of	IN	of
2	CD	2
g/day	NN	g/day
)	-RRB-	)
used	VBN	use
to	TO	to
continue	VB	continue
treatment	NN	treatment
in	IN	in
the	DT	the
maintenance	NN	maintenance
phase	NN	phase
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
the	DT	the
present	JJ	present
study	NN	study
shows	VBZ	show
that	IN	that
a	DT	a
few	JJ	few
patients	NNS	patient
cannot	MD	cannot
tolerate	VB	tolerate
adjuvant	NN	adjuvant
mitotane	NN	mitotane
following	VBG	follow
the	DT	the
first	JJ	first
months	NNS	month
of	IN	of
treatment	NN	treatment
,	,	,
proving	VBG	prove
than	IN	than
a	DT	a
careful	JJ	careful
follow-up	NN	follow-up
is	VBZ	be
necessary	JJ	necessary
.	.	.
</s>
<s type="decl">
Despite	IN	despite
mitotane	NN	mitotane
having	VBG	have
a	DT	a
reputation	NN	reputation
for	IN	for
being	VBG	be
a	DT	a
challenging	JJ	challenging
drug	NN	drug
to	TO	to
manage	VB	manage
,	,	,
adjuvant	NN	adjuvant
mitotane	NN	mitotane
treatment	NN	treatment
is	VBZ	be
feasible	JJ	feasible
when	WRB	when
patients	NNS	patient
are	VBP	be
managed	VBN	manage
in	IN	in
expert	JJ	expert
centers	NNS	center
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
some	DT	some
patients	NNS	patient
were	VBD	be
unable	JJ	unable
to	TO	to
tolerate	VB	tolerate
the	DT	the
drug	NN	drug
,	,	,
exhibiting	VBG	exhibit
neurological	JJ	neurological
toxicity	NN	toxicity
even	RB	even
when	WRB	when
exposed	VBN	expose
to	IN	to
“	``	''
normal	JJ	normal
”	''	''
mitotane	NN	mitotane
concentrations	NNS	concentration
,	,	,
confirming	VBG	confirm
the	DT	the
relevance	NN	relevance
of	IN	of
individual	JJ	individual
factors	NNS	factor
in	IN	in
mitotane	NN	mitotane
metabolism	NN	metabolism
.	.	.
</s>
</p>
<p>
<s type="decl">
Strengths	NNS	strength
of	IN	of
the	DT	the
present	JJ	present
study	NN	study
are	VBP	be
the	DT	the
thorough	JJ	thorough
characterization	NN	characterization
of	IN	of
adjuvant	JJ	adjuvant
mitotane	NN	mitotane
treatment	NN	treatment
of	IN	of
ACC	NNP	ACC
patients	NNS	patient
following	VBG	follow
surgical	JJ	surgical
removal	NN	removal
of	IN	of
the	DT	the
tumor	NN	tumor
and	CC	and
the	DT	the
large	JJ	large
data	NNS	datum
set	NN	set
,	,	,
considering	VBG	consider
the	DT	the
rarity	NN	rarity
of	IN	of
the	DT	the
disease	NN	disease
.	.	.
</s>
<s type="decl">
This	DT	this
allowed	VBD	allow
for	IN	for
the	DT	the
capture	NN	capture
of	IN	of
details	NNS	detail
of	IN	of
mitotane	NN	mitotane
treatment	NN	treatment
that	WDT	that
were	VBD	be
not	RB	not
available	JJ	available
in	IN	in
previous	JJ	previous
studies	NNS	study
and	CC	and
led	VBD	lead
to	IN	to
observations	NNS	observation
that	WDT	that
may	MD	may
be	VB	be
useful	JJ	useful
to	IN	to
informing	VBG	inform
future	JJ	future
practice	NN	practice
.	.	.
</s>
<s type="multiple">
However	RB	however
,	,	,
we	PRP	we
should	MD	should
acknowledge	VB	acknowledge
the	DT	the
limits	NNS	limit
of	IN	of
a	DT	a
retrospective	JJ	retrospective
analysis	NN	analysis
,	,	,
and	CC	and
that	IN	that
our	PRP$	our
results	NNS	result
are	VBP	be
not	RB	not
generalizable	JJ	generalizable
to	IN	to
patients	NNS	patient
who	WP	who
discontinue	VBP	discontinue
treatment	NN	treatment
within	IN	within
six	CD	6
months	NNS	month
for	IN	for
intolerability	NN	intolerability
or	CC	or
patients	NNS	patient
with	IN	with
early	JJ	early
ACC	NN	ACC
recurrence	NN	recurrence
.	.	.
</s>
<s type="decl">
The	DT	the
inclusion	NN	inclusion
criteria	NNS	criterion
of	IN	of
the	DT	the
study	NN	study
produced	VBD	produce
an	DT	a
immortal	JJ	immortal
time	NN	time
of	IN	of
six	CD	6
months	NNS	month
that	WDT	that
may	MD	may
have	VB	have
enriched	VBN	enrich
our	PRP$	our
series	NN	series
of	IN	of
a	DT	a
higher	JJR	high
number	NN	number
of	IN	of
low-risk	JJ	low-risk
ACC	NNP	ACC
compared	VBN	compare
to	IN	to
recently	RB	recently
published	VBN	publish
series	NNS	series
.	.	.
</s>
</p>
</text>